Breaking News Instant updates and real-time market news.

TEVA

Teva

$30.22

0.69 (2.34%)

, REGN

Regeneron

$475.79

-10.11 (-2.08%)

06:19
06/12/17
06/12
06:19
06/12/17
06:19

Teva seeks to refresh board with four new members, Reuters reports

Teva (TEVA) is looking to refresh its board with the selection of four new nominees, including Murray Goldberg, a former CFO at Regeneron (REGN), Roberto Mignone, founder of Bridger Management, Perry Nisen, a former GlaxoSmithKline (GSK) executive, and Chemi Peres, founder of venture capital group Pitango, Reuters reports. Teva's stock price has plunged over the last few months following a series of acquisitions and delayed drug launches, as well as new generic competition for its MS drug Copaxone. The company is also re-nominating chairman Sol Barer, the report says. Reference Link

TEVA

Teva

$30.22

0.69 (2.34%)

REGN

Regeneron

$475.79

-10.11 (-2.08%)

GSK

GlaxoSmithKline

$43.51

-0.28 (-0.64%)

  • 22

    Jun

  • 30

    Aug

TEVA Teva
$30.22

0.69 (2.34%)

04/25/17
WELS
04/25/17
NO CHANGE
WELS
Novartis results highlight tough pricing environment, says Wells Fargo
This morning's Q1 results from Novartis' (NVS) Sandoz division highlight the difficult U.S. generic price environment, Wells Fargo analyst David Maris tells investors in a research note. Sandoz experienced pricing erosion of 8% in the quarter, which represents the largest negative impact from pricing in recent quarters, Maris writes. He expects the negative U.S. pricing environment to impact including Mallinckrodt (MNK), Teva (TEVA), Mylan (MYL) and Perrigo (PRGO). Maris remains cautious on the pricing environment for generics.
05/11/17
WELS
05/11/17
NO CHANGE
WELS
Market Perform
Teva faces 'underappreciated risk' from major generic RFPs, says Wells Fargo
Wells Fargo analyst David Maris noted that Teva's generic drug price erosion came in at 7% in Q1, adding that Teva's management, which previously indicated that they expected price erosion in the U.S. to be 5%, "did not explain well" how the factors that negatively impacted prices were not fully anticipated. Also, there are currently two major generic Request for Proposals out for bid - one from Express Scripts (ESRX), Albertson's and Kroger (KR) and one from Walmart (WMT) and McKesson (MCK) - and the potential price reset from these is an "underappreciated risk" facing Teva, added Maris, who keeps a Market Perform rating on the stock.
05/02/17
LEHM
05/02/17
NO CHANGE
Target $70
LEHM
Overweight
Neurocrine price target raised to $70 from $60 at Barclays
Barclays analyst Geoff Meacham raised his price target for Neurocrine Biosciences (NBIX) to $70 and maintains an Overweight rating on the shares. Ingrezza pricing came in ahead of expectations at $50,000 per year net, Meacham tells investors in a research note. He believes the net cost of Ingrezza is favorably positioned relative to Teva's (TEVA) Austedo.
05/01/17
JEFF
05/01/17
NO CHANGE
Target $67
JEFF
Buy
Jefferies ups Neurocrine target on 'encouraging' doctor survey
Jefferies analyst Biren Amin raised his price target for Neurocrine Biosciences (NBIX) to $67 from $65 after his firm, for the second time, surveyed 50 U.S. doctors on the current and future Tardive Dyskinesia treatment landscape. The shares closed Friday down 19c to $53.40. The respondents estimate "significant uptake" of both Neurocrine's valbenazine and Teva's (TEVA) Austedo with a "clear preference" for valbenazine, Amin tells investors in a research note. The analyst now expects valbenazine to capture a larger share than Austedo in moderate-to-severe Tardive Dyskinesia. Amin keeps a Buy rating on Neurocrine shares.
REGN Regeneron
$475.79

-10.11 (-2.08%)

05/05/17
UBSW
05/05/17
NO CHANGE
Target $489
UBSW
Buy
Regeneron price target raised to $489 from $446 at UBS
UBS analyst Carter Gould raised his price target on Regeneron to $489 from $446 following Q1 results. The analyst lowered his Eylea U.S. sales estimates based on Q1 trends, but he saw positives in the Dupixent update, including strong demand in atopic dermatitis. Also, the company has seen positive proof-of-concept data in eosinophilic esophagitis, which he noted was not in Street models. Gould reiterated his Buy rating on Regeneron shares.
05/05/17
ADAM
05/05/17
UPGRADE
Target $484
ADAM
Buy
Regeneron upgraded to Buy at Canaccord
As reported previously, Canaccord analyst John Newman upgraded Regeneron to Buy from Hold. The analyst cited the strong investor sentiment toward the Dupixent launch, which he believes will drive the shares higher into Q2 and Q3 earnings. He also believes there will be less focus on Eylea revenues, despite slowing growth. Newman raised his price target to $484 from $375 on Regeneron shares.
05/05/17
LEER
05/05/17
NO CHANGE
Target $493
LEER
Outperform
Regeneron price target raised to $493 from $448 at Leerink
Leerink analyst Geoffrey Porges raised his price target for Regeneron to $493 from $448 following quarterly results, and given the strength of peer company multiples and greater conviction about long-term profitability. The analyst reiterates an Outperform rating on the shares.
05/23/17
JEFF
05/23/17
NO CHANGE
Target $418
JEFF
Hold
Regeneron approval expected, but positive, says Jefferies
Jefferies analyst Biren Amin says that while the FDA approval of Regeneron's (REGN) Kevzara for the treatment of adult patients with moderate to severe active rheumatoid arthritis was expected, it is a positive. The label is in line with expectations and includes a risk of serious infections similar to Humira's (HUM) label, Amin tells investors in a research note. He notes that Regeneron disclosed a $39,000 wholesale acquisition cost for Kevzara, which is 30% lower than TNF competitors. The analyst has a Hold rating on Regeneron with a $418 price target.
GSK GlaxoSmithKline
$43.51

-0.28 (-0.64%)

05/26/17
05/26/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. GlaxoSmithKline (GSK) upgraded to Buy from Hold at Berenberg with analyst Alistair Campbell saying Glaxo's long-term value is emerging and the market underappreciates the strength and breadth of its diversified business. 2. Rayonier Advanced Materials (RYAM) was upgraded to Buy from Hold at Vertical Research and to Buy from Neutral at BofA/Merrill. 3. Red Robin (RRGB) upgraded to Buy from Hold at Canaccord with analyst Lynne Collier citing greater confidence in its top-line drivers and in stable to improving casual dining trends. Collier raised her price target to $90 from $72 on Red Robin shares. 4. Star Bulk Carriers (SBLK) upgraded to Buy on valuation at Seaport Global with analyst Magnus Fyhr citing the pullback in shares and favorable drybulk market fundamentals. Fyhr raised his price target on Star Bulk shares to $13 from $11.50. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/30/17
LEER
05/30/17
NO CHANGE
Target $74
LEER
Market Perform
Gilead HIV combo data should reassure investors, says Leerink
Leerink analyst Geoffrey Porges said Gilead's (GILD) Phase 3 data for its HIV combination treatment featuring bictegravir should "provide significant reassurance for investors" given that the drug is an essential part of the company's HIV strategy and portfolio and was found to be equal to, though not better than, the "gold standard," namely GlaxoSmithKline's (GSK) dolutegravir combo. Porges, who attributes $12-13 per share in value from bictegravir in his current model for Gilead, notes that his peak global forecast of $10.6B for bictegravir containing combination revenue is nearly double the current consensus peak sales estimate of $5.6B. Porges keeps a Market Preform rating and $74 price target on Gilead shares.
05/30/17
JPMS
05/30/17
NO CHANGE
JPMS
Overweight
JPMorgan 'generally encouraged' by Gilead bictegravir data
After Gilead (GILD) announced top-line data from four Phase 3 studies of its HIV combo regimen containing bictegravir, JPMorgan analyst Cory Kasimov said he was "generally encouraged by the news, though not entirely surprised" given the previously communicated Phase 2 results. As he has previously noted, Kasimov thinks the launch of the bictegravir combo in 2018 could be key for Gilead to help maintain market share in the face of continued growth of GlaxoSmithKline's (GSK) dolutegravir combo and a wave of patent expirations. The analyst keeps an Overweight rating on Gilead shares.
06/06/17
WELS
06/06/17
NO CHANGE
WELS
Amazon may be the next threat to drug pricing, says Wells Fargo
After CNBC recently reported that Amazon (AMZN) is considering going into the prescription pharmacy business in the U.S., Wells Fargo surveyed nearly 2,900 U.S. adults and found that 54% of those polled said they would use or would probably use "Amazon Pharmacy." While the e-commerce giant has not confirmed its U.S. pharmacy interest, if it did enter the market analyst David Maris believes it could see fast adoption and "usher in a new age of price transparency." Maris also wonders if pharmacy "may be just the beginning" and if Amazon eyes the "even larger prize" of fully integrated digital healthcare. Publicly traded large-cap pharmaceuticals companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded retail pharmacy operators include CVS Health (CVS), Walgreens (WBA), Fred's (FRED) and Rite Aid (RAD).

TODAY'S FREE FLY STORIES

JPM

JPMorgan

$90.56

-0.18 (-0.20%)

, AAPL

Apple

$157.50

-0.36 (-0.23%)

11:43
08/21/17
08/21
11:43
08/21/17
11:43
Periodicals
JPMorgan pledges up to $2M to anti-hate groups, CNBC reports »

JPMorgan (JPM) is…

JPM

JPMorgan

$90.56

-0.18 (-0.20%)

AAPL

Apple

$157.50

-0.36 (-0.23%)

FOX

21st Century Fox

$26.79

-0.1 (-0.37%)

FOXA

21st Century Fox

$27.26

-0.09 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 07

    Sep

  • 11

    Sep

  • 12

    Oct

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

SNA

Snap-On

$142.41

-5.55 (-3.75%)

11:41
08/21/17
08/21
11:41
08/21/17
11:41
Technical Analysis
Technical View: Snap-On falls to session lows, analyst action »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 06

    Sep

TV

Grupo Televisa

$25.75

0.31 (1.22%)

11:40
08/21/17
08/21
11:40
08/21/17
11:40
Options
Put seller opens a large position in Grupo Televisa »

Put seller opens a large…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:40
08/21/17
08/21
11:40
08/21/17
11:40
General news
Fed's inaugural SCE Labor Market Survey surprisingly dour: »

Fed's inaugural SCE…

CYH

Community Health

$7.63

0.595 (8.46%)

11:37
08/21/17
08/21
11:37
08/21/17
11:37
Hot Stocks
ASL Strategic Value Fund calls on Community Health board to replace CEO »

ASL Strategic Value Fund…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 06

    Sep

11:37
08/21/17
08/21
11:37
08/21/17
11:37
Hot Stocks
Breaking Hot Stocks news story  »

Stellus Capital…

BRK.A

Berkshire Hathaway

$267,800.00

423 (0.16%)

, BRK.B

Berkshire Hathaway

$177.86

0.3 (0.17%)

11:36
08/21/17
08/21
11:36
08/21/17
11:36
Hot Stocks
Berkshire Hathaway Energy agreement to acquire Oncor terminated by EFH »

Berkshire Hathaway Energy…

BRK.A

Berkshire Hathaway

$267,800.00

423 (0.16%)

BRK.B

Berkshire Hathaway

$177.86

0.3 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$10.62

0.06 (0.57%)

, AAPL

Apple

$157.50

-0.36 (-0.23%)

11:36
08/21/17
08/21
11:36
08/21/17
11:36
Periodicals
Ford CTO: Autonomous vehicles need more than just software, Axios reports »

Ford (F) CTO Ken…

F

Ford

$10.62

0.06 (0.57%)

AAPL

Apple

$157.50

-0.36 (-0.23%)

GOOG

Alphabet

$910.67

-0.31 (-0.03%)

GOOGL

Alphabet Class A

$926.18

-1.48 (-0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 24

    Aug

PNW

Pinnacle West

$89.26

-0.03 (-0.03%)

11:35
08/21/17
08/21
11:35
08/21/17
11:35
Hot Stocks
Pinnacle West says Commissioner Burns files petition to vacate ACC's order »

On August 18, the ACC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:34
08/21/17
08/21
11:34
08/21/17
11:34
General news
3-Month Bill Auction Total Amount data reported »

3-Month Bill Auction…

11:34
08/21/17
08/21
11:34
08/21/17
11:34
General news
6-Month Bill Auction Total Amount data reported »

6-Month Bill Auction…

MCD

McDonald's

$158.46

0.7 (0.44%)

11:31
08/21/17
08/21
11:31
08/21/17
11:31
Periodicals
McDonald's to close 169 outlets in northern, eastern India, Reuters reports »

McDonald's is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

AEO

American Eagle

$10.40

-0.715 (-6.44%)

11:30
08/21/17
08/21
11:30
08/21/17
11:30
Options
American Eagle puts active as shares touch 52-week lows »

American Eagle puts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

PNW

Pinnacle West

$89.00

-0.2899 (-0.32%)

11:29
08/21/17
08/21
11:29
08/21/17
11:29
Earnings
Breaking Earnings news story on Pinnacle West »

Pinnacle West sees FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IYR

DJ US Real Estate Index Fund

$79.79

0.61 (0.77%)

, XLV

Health Care Select Sector SPDR

$78.27

0.27 (0.35%)

11:25
08/21/17
08/21
11:25
08/21/17
11:25
Technical Analysis
S&P 500 trades near top of range for the day as mid-session approaches »

The S&P 500 (SPX) is…

IYR

DJ US Real Estate Index Fund

$79.79

0.61 (0.77%)

XLV

Health Care Select Sector SPDR

$78.27

0.27 (0.35%)

XLP

Consumer Staples Sector SPDR

$55.35

0.145 (0.26%)

XLB

S&P Select Materials SPDR

$53.82

0.105 (0.20%)

XLU

Utilities SPDR

$54.56

0.06 (0.11%)

XLE

Energy Select Sector SPDR

$62.05

-0.27 (-0.43%)

XLF

Financial Select Sector

$24.49

-0.13 (-0.53%)

XLK

Technology Select Sector SPDR

$56.83

-0.245 (-0.43%)

SPY

SPDR S&P 500 ETF Trust

$242.46

-0.25 (-0.10%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXDX

Accelerate Diagnostics

$21.70

-1.85 (-7.86%)

11:22
08/21/17
08/21
11:22
08/21/17
11:22
Recommendations
Accelerate Diagnostics analyst commentary  »

Piper sees several…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETE

Energy Transfer Equity

$16.54

-0.135 (-0.81%)

11:20
08/21/17
08/21
11:20
08/21/17
11:20
Options
Short-term call buyer in Energy Transfer Equity »

Short-term call buyer in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

11:17
08/21/17
08/21
11:17
08/21/17
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

11:16
08/21/17
08/21
11:16
08/21/17
11:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
08/21/17
08/21
11:15
08/21/17
11:15
General news
Treasury announced a $30 B 4-week bill sale for Tuesday »

Treasury announced a $30…

11:15
08/21/17
08/21
11:15
08/21/17
11:15
General news
Breaking General news story  »

3-Month Bill Auction to…

11:15
08/21/17
08/21
11:15
08/21/17
11:15
General news
Breaking General news story  »

6-Month Bill Auction to…

PAYX

Paychex

$54.99

0.01 (0.02%)

11:11
08/21/17
08/21
11:11
08/21/17
11:11
Hot Stocks
Paychex acquires HR Outsourcing Holdings; terms not disclosed »

Paychex announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

  • 30

    Oct

AXDX

Accelerate Diagnostics

$21.70

-1.85 (-7.86%)

11:10
08/21/17
08/21
11:10
08/21/17
11:10
Hot Stocks
Accelerate Diagnostics CEO trades 223K shares for shares of exchange fund »

In a regulatory filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FEYE

FireEye

$13.98

-0.01 (-0.07%)

11:10
08/21/17
08/21
11:10
08/21/17
11:10
Options
Vote of confidence in FireEye »

Vote of confidence in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 11

    Sep

  • 19

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.